Meeting
2011 ASCO Annual Meeting
Paradigm shift in the management of high-intermediate risk stage I endometrial cancer.
Authors
J. O. Schorge
Massachusetts General Hospital, Boston, MA
J. O. Schorge , A. H. Russell , L. A. Garrett , A. Goodman , M. G. del Carmen , W. B. Growdon , D. M. Boruta II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Uterine Cancer
Citation
J Clin Oncol 29: 2011 (suppl; abstr 5103)
Abstract #
5103
Poster Bd #
22C
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase III trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate- or high-risk endometrial cancer. ENGOT-EN2-DGCG/EORTC 55102.
First Author: Mansoor Raza Mirza
Poster
2019 ASCO Annual Meeting
A comparison of adjuvant therapy approaches for patients with early-stage uterine serous carcinoma.
First Author: Katherine Kurnit
Poster
2018 ASCO Annual Meeting
STATEC: A randomised trial of non-selective versus selective adjuvant therapy in high risk apparent stage 1 endometrial cancer.
First Author: Tim Mould
Poster
2017 ASCO Annual Meeting
Association of delayed adjuvant therapy and overall survival in early stage endometrial cancer.
First Author: Leo Luo